Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC7 | O00311 | 1/20 | 0.47 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.45 |
| ▸ | DCAF1 | Q9Y4B6 | 1/20 | 0.44 |
| ▸ | HPGDS | O60760 | 1/20 | 0.44 |
| ▸ | CSNK1E | P49674 | 8/20 | 0.42 |
| ▸ | CSNK1D | P48730 | 7/20 | 0.42 |
| ▸ | PARP1 | P09874 | 1/20 | 0.41 |
| ▸ | JAK2 | O60674 | 2/20 | 0.41 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.41 |
| ▸ | JAK3 | P52333 | 1/20 | 0.41 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.41 |
| ▸ | FYN | P06241 | 1/20 | 0.40 |
| ▸ | ADCY10 | Q96PN6 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22886635 | 0.87 | KMT2A (0.50) | DCAF1TRPA1 | |
| SCHEMBL15428638 | 0.86 | DCAF1 (0.54) | DCAF1PARP1JAK2 | |
| SCHEMBL15750734 | 0.82 | CA12 (0.55) | MAP4K4CSNK1ECSNK1D | |
| SCHEMBL26424817 | 0.82 | CA12 (0.53) | DCAF1PARP1 | |
| SCHEMBL20028187 | 0.82 | JAK2 (0.55) | CSNK1DJAK2JAK3 | |
| SCHEMBL31457082 | 0.78 | SSTR2 (0.38) | DCAF1CSNK1ECSNK1DPARP1 | |
| SCHEMBL15428594 | 0.78 | ADCY10 (0.44) | MAP4K4CSNK1ECSNK1DADCY10 | |
| SCHEMBL31457048 | 0.76 | CSNK1D (0.46) | CSNK1ECSNK1DPARP1 | |
| SCHEMBL20027495 | 0.76 | DCAF1 (0.53) | DCAF1 | |
| SCHEMBL21854327 | 0.76 | DCAF1 (0.53) | DCAF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160244456-A1 | PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS | GENENTECH, INC. (US) | 2016-08-25 | — | — | US | disclosed |
| EP-2962566-A1 | PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS | Genentech, Inc. (US) | 2016-01-06 | — | — | EP | disclosed |
| EP-2348860-B1 | PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS | GENENTECH INC (US) | 2015-05-27 | — | — | EP | disclosed |
| US-20140107099-A1 | PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS | GENENTECH, INC. (US) | 2014-04-17 | — | — | US | disclosed |
| US-8637526-B2 | Pyrazolopyrimidine JAK inhibitor compounds and methods | GENENTECH, INC. (US) | 2014-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140107099-A1 | PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS | JAK2, JAK1, JAK3 | CDC7 341/4885MAP4K4 112/4885DCAF1 808/4885 |
| US-20160244456-A1 | PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS | JAK2, JAK1, JAK3 | CDC7 341/4885MAP4K4 112/4885DCAF1 808/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.